Hi everyone,
This is piece I have written about HVivo, as a shareholder, but I would love to get some constructive thoughts on the below. I’m 24 years old and haven’t been investing for many years so still finding my feet in this space. I am also dyslexic, so if things don’t read very well please bear with me.
Many thanks
Olly
How is HVivo going to progress to the next level?
Hvivo is a really interesting stock in so many ways. I’m going to look into where they have come from, their situation today and where they are going. It is key player in the challenge trails and clinical services sector, niche part of the healthcare market. They are growing very well with contracted revenues for this year complete and have contracted 40% of 2024. However they haven’t been the easiest company to be a shareholder of. All of which will be explained later.
Hvivo is world leader in challenge trials, a significantly faster and more effective way of testing vaccines and anti viral drugs. Challenge trials are where volunteers are inoculated with a disease or virus to test the effectiveness of a particular drug or vaccine. Challenge trials can take the testing phase down from 2 years and 40,000 volunteers in the open world and all the complications that involved, to 6 weeks and under 100 volunteers. This was proven recently with the rapid testing of the Covid vaccines. More recent proof of this was shown earlier this year by SAB Biotherapeutics an American Bio-tech that has received fast track and break through therapy designations from the data collected in their phase 2 trial that was carried out by Hvivo. They are the answer to the worlds health care testing needs.
Today Hvivo is a fast growing cash rich company in a very interesting and profitable area of health care. They do not take any regulatory risks in developing drugs. They are simply a picks and shovels company suppling data and testing for those who are digging for gold. Hvivo is now running an end to end testing service for clients. From characterising the challenge agent to carrying out the trial, and then analysing the data. Offering this end to end service is what is setting them apart from their competition and is also what holds their high reputation. This year has been an impressive…
